GSK Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
0
CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4677454-cytomx-therapeutics-inc-ctmx-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 11, 2024 - CytomX Therapeutics, Inc. (NASDAQ:NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ETCompany ParticipantsChris Ogden - Senior Vice...
0
Here's Why Investors May Bet on BioMarin (BMRN) Stock Now
https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118
Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
https://www.zacks.com/stock/news/2214493/ionis-ions-donidalorsen-meets-late-stage-hae-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214493
Jan 23, 2024 - Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
0
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213712
Jan 22, 2024 - Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
0
Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates
https://www.zacks.com/stock/news/2213525/alvotech-alvo-up-on-bla-update-for-two-biosimilar-candidates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213525
Jan 22, 2024 - The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.
0
TransCode (RNAZ) Down 50% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213010
Jan 19, 2024 - TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
0
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213007
Jan 19, 2024 - ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
0
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
https://www.zacks.com/stock/news/2212927/mesoblast-meso-up-on-rare-pediatric-disease-tag-for-heart-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212927
Jan 19, 2024 - Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
0
Page 1>